Microgynon (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Microgynon, is a combined oral contraceptive presented as a 0.03 mg / 0.15 mg oral tablet for oral use. It prevents pregnancy in women of reproductive age by providing hormonal contraception. The formulation also contains levonorgestrel, a progestogenic component that works synergistically to inhibit ovulation and modify cervical mucus.

GNH USA supplies Microgynon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Microgynon, a combined oral contraceptive, is indicated for hormonal contraception and related reproductive health conditions. - Prevention of pregnancy: provides reliable contraception for women seeking to avoid conception and supports family planning goals. - Regulation of menstrual cycle: helps achieve more predictable periods, reduces the duration and volume of menstrual bleeding, and can improve cycle regularity. - Management of dysmenorrhea: can lessen menstrual pain associated with primary dysmenorrhea, offering symptomatic relief for many users.

Microgynon may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Breast tenderness - Headache - Spotting between periods

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Severe liver dysfunction - Anaphylactic reaction

When prescribing Microgynon, clinicians should consider several safety measures. - Assess cardiovascular risk: evaluate personal or family history of thromboembolic events before prescribing. - Review smoking status: avoid use in women over 35 who smoke cigarettes. - Check hepatic function: use with caution in patients with liver disease or abnormal liver enzymes. - Monitor blood pressure: measure regularly, especially in patients with hypertension. - Counsel on missed tablets: advise prompt action to maintain contraceptive efficacy. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Microgynon can interact with other medicines, requiring attention to potential changes in effectiveness or safety.

Major Interactions (Avoid): - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce contraceptive effectiveness. - Antiretroviral protease inhibitors (e.g., ritonavir): may increase hormone levels and risk of side effects. - St. John’s wort: may markedly decrease efficacy.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., fluconazole): may increase plasma hormone concentrations. - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly reduce effectiveness. - SSRIs (e.g., fluoxetine): may increase risk of bleeding.